Esperion Therapeutics Inc (ESPR)
2.68
+0.06
(+2.29%)
USD |
NASDAQ |
Mar 28, 16:00
2.69
+0.01
(+0.37%)
After-Hours: 20:00
Esperion Therapeutics Enterprise Value: 675.29M for March 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 28, 2024 | 675.29M |
March 27, 2024 | 664.19M |
March 26, 2024 | 678.99M |
March 25, 2024 | 664.19M |
March 22, 2024 | 603.12M |
March 21, 2024 | 569.81M |
March 20, 2024 | 584.61M |
March 19, 2024 | 564.26M |
March 18, 2024 | 558.71M |
March 15, 2024 | 562.41M |
March 14, 2024 | 558.71M |
March 13, 2024 | 584.61M |
March 12, 2024 | 558.71M |
March 11, 2024 | 571.66M |
March 08, 2024 | 584.61M |
March 07, 2024 | 601.27M |
March 06, 2024 | 634.58M |
March 05, 2024 | 623.47M |
March 04, 2024 | 630.88M |
March 01, 2024 | 651.23M |
February 29, 2024 | 643.83M |
February 28, 2024 | 654.93M |
February 27, 2024 | 716.00M |
February 26, 2024 | 666.04M |
February 23, 2024 | 662.34M |
Date | Value |
---|---|
February 22, 2024 | 666.04M |
February 21, 2024 | 662.34M |
February 20, 2024 | 675.29M |
February 16, 2024 | 677.14M |
February 15, 2024 | 671.59M |
February 14, 2024 | 646.34M |
February 13, 2024 | 633.81M |
February 12, 2024 | 644.55M |
February 09, 2024 | 640.97M |
February 08, 2024 | 640.97M |
February 07, 2024 | 649.92M |
February 06, 2024 | 640.97M |
February 05, 2024 | 605.18M |
February 02, 2024 | 571.19M |
February 01, 2024 | 549.72M |
January 31, 2024 | 562.24M |
January 30, 2024 | 540.77M |
January 29, 2024 | 567.61M |
January 26, 2024 | 560.45M |
January 25, 2024 | 551.51M |
January 24, 2024 | 542.56M |
January 23, 2024 | 560.45M |
January 22, 2024 | 433.50M |
January 19, 2024 | 418.13M |
January 18, 2024 | 433.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
202.67M
Minimum
Apr 25 2023
1.831B
Maximum
Feb 13 2020
618.72M
Average
577.86M
Median
Enterprise Value Benchmarks
United Therapeutics Corp | 8.517B |
Heron Therapeutics Inc | 508.25M |
Aldeyra Therapeutics Inc | 64.91M |
First Wave BioPharma Inc | 5.495M |
Cyclacel Pharmaceuticals Inc | -0.5965M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -56.34M |
Revenue (Quarterly) | 32.25M |
Total Expenses (Quarterly) | 74.62M |
EPS Diluted (Quarterly) | -0.50 |
Gross Profit Margin (Quarterly) | 64.49% |
Profit Margin (Quarterly) | -174.7% |
Earnings Yield | -79.10% |
Normalized Earnings Yield | -79.10 |